Manman Tian
Nanjing, 210008, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Corrigendum to "A rapid ex vivo co-culture of memory-like NK and activated T cells enhances anti-tumor response in gastric cancer" [Int. Immunopharmacol. 166 (2025) 115569].
Journal: International immunopharmacology
Published: October 18, 2025
Novel tetrameric bispecific KK-LC-1×CD16A-armed memory-like NK cells enhance antitumor efficacy in gastric cancer.
Journal: Journal for immunotherapy of cancer
Published: September 21, 2025
Anti-MSLN chimeric antigen receptor-like NK cell therapy with tumor-penetrating capacity (uCAR-like NK) for solid tumors.
Journal: Signal transduction and targeted therapy
Published: August 12, 2025
A rapid ex vivo co-culture of memory-like NK and activated T cells enhances anti-tumor response in gastric cancer.
Journal: International immunopharmacology
Published: July 24, 2025
Verteporfin-Mediated In Situ Nanovaccine Based on Local Conventional-Dose Hypofractionated Radiotherapy Enhances Antitumor and Immunomodulatory Effect.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: November 26, 2024
Combining iRGD with HuFOLactis enhances antitumor potency by facilitating immune cell infiltration and activation.
Journal: Human vaccines & immunotherapeutics
Published: August 05, 2024
An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: 'R-ISV-FOLactis' trial.
Journal: Future oncology (London, England)
Published: July 22, 2024
Mycobacterium smegmatis enhances shikonin-induced immunogenic cell death-an efficient in situ tumor vaccine strategy.
Journal: Journal of biomedical research
Published: May 29, 2024
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors.
Journal: Future oncology (London, England)
Published: March 06, 2024
Efficacy of MAGE-A4 long peptide as a universal immunoprevention cancer vaccine.
Journal: Cancer cell international
Published: January 03, 2024
Correction: iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.
Correction: iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.
Journal: Journal of translational medicine
Published: May 09, 2023
Last Updated: 09/26/2026